Quintiles’ Jay Norman tells Outsourcing-pharma that data sharing and patient and payer concerns will drive drug industry competition and clinical development decisions accord to new research.
A new study believes vaccine manufacturers from developing countries may be able to produce a HPV vaccine at a lower cost without infringing on the numerous patents drug makers have taken out on the vaccine technology.
Merck & Co is to close or sell eight manufacturing plants and a further eight R&D laboratories as part of efforts to cuts its workforce by 15 per cent.
InhibOx and the Cambridge Crystallographic Data Centre (CCDC) say new drug discovery services partnership is motivated by market need for CADD expertise.
The rapidly evolving Asian drug manufacturing sector represents both an opportunity and a challenge for the fine chemicals and molecules industry, according to SAFC president Gilles Cottier.
Ireland-based Firecrest Clinical says focusing on trial specific training and visits for principal investigators can speed recruitment, cut protocol deviations and produce cleaner data.
Quintiles is establishing its first Prime Site in Asia by entering into a strategic alliance with the University Malaya Medical Centre (UMMC) in Malaysia.
The opening of a New York office will help communicate Clintec’s global reach to US Pharmaceutical according to new associate director of US business operations, Susan Pavone.
Indian CROs Max Neeman International and QED Pharmaceutical Services have both added US Food and Drug Administration’s (FDA) CDISC compliance to their data management offering this month.
Demand for biomarker analysis is strong, but the pace of technological change is causing an investment headache for CROs according to a new report by Industry Standard Research (ISR).
Suzhou Erye, a subsidiary of NeoStem Pharmaceutical, has passed inspection by the Chinese Food and Drug Administration (SFDA) meaning the company's new manufacturing facility will go ahead with the manufacture of penicillin and cephalosporin powder...
India’s oldest pharmaceutical company Alembic went one step closer to the biggest restructuring in its history as its board approved the demerging of its main pharmaceutical business into a separate subsidiary company, Alembic Pharma.
Sanofi-Aventis will build a new manufacturing plant in King Abdullah Economic City (KAEC) in Saudi Arabia through an agreement with the Emaar development company (ECC).
The Singaporean government has launched two new certification courses for clinical researchers in a bid to “deepen the pool of skilled manpower” available to the country’s rapidly expanding contract research sector.
A US group representing hospitals in New York wants to accelerate clinical research process by improving trial access to electronic patient records, while maintaining patient privacy.
Tanabe Research Labs (TRL) has revealed details of its new San Diego facility in which the revised layout of the site allows a fresh focus on antibody and biological approaches to autoimmune diseases such as diabetes and rheumatoid arthritis.
Regulus Therapeutics’ microRNA satellite technology has won the firm its biggest deal to date with French drugmaker Sanofi-Aventis agreeing a development accord worth up to $750m (€606m).
New Gerresheimer CEO Uwe Roehrhoff wants the German firm to become the pharmaceutical and biopharmaceutical industry “first choice” partner for high-tech packaging.
US CRO Kendle has opened a new services centre in India, attracted by the country’s thriving contract research sector and favourable climate for clinical trials.
US drugmaker Merck & Co’s new deal with Adcock Ingram proves the FIFA football World Cup isn’t the only thing attracting people to South Africa this summer.
ViroPharma is seeking permission from the Food and Drug Administration (FDA) to increase production of Cinryze to an industrial scale as part of its ongoing expansion activities.
French drug maker Sanofi-Aventis continues to spearhead the fight for a more secure pharmaceutical supply chain by launching an anti-counterfeit medication initiative in Egypt.
Schott Pharmaceutical Packaging has revealed details of its US-based ready-to-fill syringe production line capabilities in a manufacturing sector that has traditionally been the strong hold of countries like Germany and France.
The role of the pharma industry in supporting the COE anti-counterfeiting treaty, which aims to criminalise activities, “cannot be underestimated”, according to a directorate member.
Nearly half of healthcare supply chain executives are planning to expand into emerging markets in the next 18 months, according to a UPS survey, but are concerned about the process.
PhRMA, EFPIA, JPMA and the IFPMA have adopted a “joint position” that calls on member companies to submit summaries of all Phase III studies and those of “significant medical importance” for publication in peer reviewed journals.
The ACRO says greater regulatory harmonization, expansion of trial registries and clarification of liability issues are needed to address the “alarming” drop in number of investigators participating in trials in US and Europe
Bristol-Myers Squibb (B-MS) has inked deals with Icon and Parexel to support the large volume of clinical development work it expects to perform in coming years.
Parabolic Drugs will enter India’s CRAMS sector with new dedicated manufacturing facilities designed to attract “global innovator companies” enabling its business to grow in regulated markets.
Patheon has posted a 12 per cent growth in operating profit in the second quarter and said there is “strong evidence” the business environment is improving.
